Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 10.62B +108.5% |
| Revenue (ttm) | 638.50M +65.5% |
| Net Income | -183.17M |
| EPS | -3.68 |
| Shares Out | 51.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,635,562 |
| Open | 207.23 |
| Previous Close | 207.75 |
| Day's Range | 198.02 - 209.14 |
| 52-Week Range | 96.09 - 217.00 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 212.88 (+3.08%) |
| Earnings Date | May 4, 2026 |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]
Financial Performance
In 2025, Axsome Therapeutics's revenue was $638.50 million, an increase of 65.55% compared to the previous year's $385.69 million. Losses were -$183.17 million, -36.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price target is $212.88, which is an increase of 3.08% from the latest price.
News
Axsome Therapeutics Transcript: FDA announcement
FDA approved AUVELITY as the first non-antipsychotic for agitation in Alzheimer's dementia, based on robust efficacy and safety data. Launch is set for June with strong insurance coverage and high anticipated compliance, addressing a major unmet need for millions of patients and caregivers.
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host...
US FDA approves Axsome's drug for Alzheimer's-related agitation
The U.S. Food and Drug Administration has approved Axsome Therapeutics' drug to treat agitation in patients with Alzheimer's disease, the company said on Friday.
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...
Axsome Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Strong 2025 sales and operating leverage set the stage for 2026, with a major PDUFA date for Auvelity in Alzheimer's agitation on April 30, 2026. The company is doubling its field force, advancing a robust late-stage pipeline, and expanding market access for key CNS products.
Axsome Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Auvelity continues strong growth with expanded sales force and broadening market access, while preparations advance for ADA agitation approval and new indications. Pipeline progress includes new trials for fibromyalgia, epilepsy, and narcolepsy, with multiple late-stage and early-stage programs advancing.
Axsome Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
AUVELITY continues strong growth with plans to double its sales force and expand indications, including Alzheimer's agitation pending FDA review. The pipeline is robust, with imminent NDA submissions for AXS-12 and ongoing development of Sunosi and AXS-14, targeting large, underserved markets.
Axsome Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Auvelity surpassed $500 million in sales, driven by expanded market access and a doubling of the sales force to 600 reps. The pipeline is advancing with an sNDA for Alzheimer's agitation under FDA review, new clinical trials, and strategic in-licensing, while financials approach cash flow positivity.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics Earnings Call Transcript: Q4 2025
Revenue grew 66% year-over-year to $639M, driven by Auvelity, Sunosi, and Symbravo. Auvelity surpassed $500M in sales, and the pipeline advanced with new trials and an acquisition. Cash reserves of $323M support operations into profitability.
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively
FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars
On Wednesday, the U.S. Food and Drug Administration (FDA) accepted Axsome Therapeutics Inc.'s (NASDAQ: AXSM) supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl)...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in t...
Axsome Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Awaiting FDA decision for Auvelity in Alzheimer's agitation, with robust clinical data supporting the submission. Commercial expansion is planned for both MDD and ADA, with strong market access and DTC efforts driving prescription growth. Pipeline progress includes multiple late-stage and early-stage programs.
Axsome Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Q3 saw strong sales growth across key products, with AUVELITY and SUNOSI leading performance and a successful DTC campaign boosting prescriptions. Regulatory progress continues for ADA and narcolepsy, while financials turned cash flow positive and operating leverage is expected to improve.
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of thera...
Axsome Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 saw 63% year-over-year revenue growth to $171M, led by AUVELITY, SUNOSI, and SYMBRAVO. Pipeline progress included a supplemental NDA for AXS-05 in Alzheimer's agitation and multiple late-stage trials. Cash reserves of $325.3M support operations into cash flow positivity.
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary d...
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...